Sector | Healthcare | Compare with Sector peers |
Industry | Pharmaceuticals & Drugs | Compare with Industry peers |
Website | http://www.sanofiindialtd.com | |
Market Cap | 18,696.83 Cr. | |
Enterprise Value(EV) | 18,290.33 Cr. | 2023-12 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 261.91 | Trailing Twelve Months Ending 2023-12 |
Price-Earning Ratio (PE) | 31.00 | Trailing Twelve Months Ending 2023-12 |
Industry PE | 41.54 | Trailing Twelve Months Ending 2023-12 |
Book Value / Share | 440.95 | Trailing Twelve Months Ending 2023-12 |
Price to Book Value | 18.41 | Calculated using Price: 8,118.25 |
Dividend Yield | 2.06 | Period Ending 2022-12 |
No. of Shares Subscribed | 2.30 Cr. | 23,030,622 Shares |
FaceValue | 10 | |
About Sanofi India Ltd. | ||
The company is dedicated to supporting people through their health challenges. It is a global biopharmaceutical company focused on human health. The company prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. The company stand by the few who suffer from rare diseases and the millions with long-term chronic conditions. |
1 Day |
|
+3.07% |
1 Week |
|
+6.28% |
1 Month |
|
-8.98% |
3 Month |
|
+2.45% |
6 Month |
|
+15.40% |
1 Year |
|
+45.15% |
2 Year |
|
+11.66% |
5 Year |
|
+43.43% |
10 Year |
|
+175.95% |
9 years | 2014-12 | 2015-12 | 2016-12 | 2017-12 | 2018-12 | 2019-12 | 2020-12 | 2021-12 | 2022-12 | |
Return on Equity (%) | 18.7 | 20.68 | 17.43 | 16.87 | 18.18 | 18.07 | 21.39 | 44.65 | 36.73 | |
Return on Capital Employed (%) | 26.47 | 30.96 | 27.51 | 26.38 | 28.76 | 25.75 | 29.77 | 57.98 | 49.47 | |
Return on Assets (%) | 12.84 | 13.88 | 12.3 | 9.5 | 8.37 | 8.28 | 9.24 | 17.74 | 11.95 |
Particulars | 10 years | 2014-12 Rs. Cr. | 2015-12 Rs. Cr. | 2016-12 Rs. Cr. | 2017-12 Rs. Cr. | 2018-12 Rs. Cr. | 2019-12 Rs. Cr. | 2020-12 Rs. Cr. | 2021-12 Rs. Cr. | 2022-12 Rs. Cr. | 2023-12* Rs. Cr. |
Shh. Funds | 1,486 | 1,627 | 1,883 | 2,026 | 2,219 | 2,442 | 2,119 | 2,226 | 1,276 | 1,016 | |
Non Curr. Liab. | 86 | 161 | 156 | 1,335 | 1,357 | 1,124 | 1,280 | 1,039 | 809 | 48 | |
Curr. Liab. | 656 | 617 | 502 | 962 | 1,193 | 1,674 | 1,694 | 2,290 | 2,743 | 651 | |
Minority Int. | |||||||||||
Equity & Liab. | 2,228 | 2,405 | 2,541 | 4,324 | 4,769 | 5,240 | 5,093 | 5,555 | 4,828 | 1,715 | |
Non Curr. Assets | 965 | 1,161 | 966 | 2,519 | 2,608 | 2,141 | 2,253 | 1,876 | 1,215 | 469 | |
Curr. Assets | 1,263 | 1,244 | 1,575 | 1,805 | 2,162 | 3,099 | 2,841 | 3,675 | 3,612 | 1,246 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 2,228 | 2,405 | 2,541 | 4,324 | 4,769 | 5,240 | 5,093 | 5,555 | 4,828 | 1,715 |
Particulars | 10 years | 2014-12 Rs. Cr. | 2015-12 Rs. Cr. | 2016-12 Rs. Cr. | 2017-12 Rs. Cr. | 2018-12 Rs. Cr. | 2019-12 Rs. Cr. | 2020-12 Rs. Cr. | 2021-12 Rs. Cr. | 2022-12 Rs. Cr. | 2023-12 Rs. Cr. TTM |
Net Sales | 1,977 | 2,193 | 2,367 | 2,464 | 2,771 | 3,071 | 2,902 | 2,957 | 2,770 | 2,851 | |
Other Income | 64 | 51 | 66 | 81 | 90 | 94 | 90 | 75 | 73 | 65 | |
Total Income | 2,042 | 2,245 | 2,433 | 2,544 | 2,861 | 3,165 | 2,992 | 3,031 | 2,843 | 2,916 | |
Total Expenditure | -1,639 | -1,734 | -1,832 | -1,926 | -2,148 | -2,405 | -2,189 | -2,194 | -2,067 | -2,047 | |
PBIDT | 403 | 511 | 602 | 618 | 713 | 759 | 803 | 837 | 776 | 869 | |
Interest | 0 | 0 | -2 | -1 | -1 | 0 | -2 | -2 | -2 | -2 | |
Depreciation | -97 | -113 | -119 | -102 | -103 | -100 | -82 | -67 | -42 | -40 | |
Taxation | -109 | -159 | -176 | -189 | -229 | -186 | -200 | -313 | -244 | -243 | |
Exceptional Items | 67 | 84 | -59 | -42 | 489 | 132 | 18 | ||||
PAT | 264 | 322 | 304 | 326 | 381 | 414 | 478 | 944 | 621 | 603 | |
Adjusted EPS | 114 | 140 | 132 | 142 | 165 | 180 | 208 | 411 | 270 | 262 |
Particulars | 10 years | 2013-12 Rs. Cr. | 2014-12 Rs. Cr. | 2015-12 Rs. Cr. | 2016-12 Rs. Cr. | 2017-12 Rs. Cr. | 2018-12 Rs. Cr. | 2019-12 Rs. Cr. | 2020-12 Rs. Cr. | 2021-12 Rs. Cr. | 2022-12 Rs. Cr. |
Cash Fr. Operatn. | 273 | 265 | 213 | 322 | 435 | 374 | 412 | 611 | 559 | 399 | |
Cash Fr. Inv. | -335 | 61 | 36 | -155 | -79 | -73 | 66 | 276 | 631 | 651 | |
Cash Fr. Finan. | -105 | -122 | -147 | -180 | -188 | -197 | -183 | -810 | -849 | -1,583 | |
Net Change | -168 | 205 | 102 | -13 | 168 | 104 | 295 | 78 | 341 | -533 | |
Cash & Cash Eqvt | 261 | 466 | 568 | 554 | 722 | 825 | 1,120 | 1,197 | 1,538 | 1,005 |
Thu, 28 Mar 2024
Closure of Trading Window The Trading Window of the Company shall remain closed from 1st April 2024 till 48 hours after the announcement of the Financial Results of the Company for the quarter ended 31st March 2024 to the stock exchanges. |
Thu, 28 Mar 2024
Announcement under Regulation 30 (LODR)-Resignation of Director We wish to inform you that Mr. Marc-Antoine Lucchini (DIN: 08812302) Non-Executive Director has vide his letter dated 28th March 2024 resigned from the Board of Directors of the Company with effect from the close of business hours on 28th March 2024. |
Tue, 26 Mar 2024
Announcement under Regulation 30 (LODR)-Press Release / Media Release Please find enclosed a Press Release as regards to an exclusive distribution and promotion agreement between Sanofi India Limited (SIL) and Cipla Limited for distribution and promotion of SILs Central Nervous System products in India. |
Thu, 28 Mar 2024 |
Closing Above Previous High |
Closing Above Previous High For 3 Days |
Making Higher Highs for 3 days |
Close Within 52 Week High Zone |
Close Entering 52 Week High Zone |